Laidlaw analyst Francois Brisebois reiterated a Buy rating and $26 price target on Cara Therapeutics (NASDAQ: CARA) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'May 23, 2018 12:44 PM Cara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JVMay 23, 2018 11:01 AM Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License AgreementMay 23, 2018 10:26 AM Cara Therapeutics (CARA) Reports Ex-US Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma to Commercialize KORSUVA Injection May 23, 2018 6:09 AM Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with PruritusMay 23, 2018 6:00 AM